Singaporean medical technology company Biorithm has closed a $3.5M Series A funding round, which was co-led by Adaptive Capital Partners and SEEDS Capital, the investment division of Enterprise Singapore. The firm plans to use the funds to extend the reach of its remote pregnancy management solutions, initially throughout Southeast Asia and the U.S.
- Biorithm is leading in advancing pregnancy care with cutting-edge solutions for personalized connected maternity care.
- The company aims to end preventable childbirth complications with protocol-based remote monitoring of maternal and fetal biometrics.
- The funding will primarily be used to expand to priority markets and for ongoing clinical trials conducted with healthcare establishments in Singapore and the UK.
With regional headquarters in Singapore and US headquarters in Boston, Biorithm is well-positioned for expansion. The company also plans to invest in additional research to better understand how remote care can be properly deployed to improve patient experience during the prenatal journey.
Beyond regional expansion and research, Biorithm also plans to amplify partnerships with various stakeholders worldwide to elevate maternal and infant health through accessible, personalized care and data.
The remote maternal-fetal care platform developed by Biorithm relies on novel intellectual property in the form of specialized device and algorithms. The patient-friendly Femom technology promotes patient monitoring, individualized guidance, and the integration of predictive analytics that help clinicians identify early complication signs.
Adaptive Capital Partners and SEEDS Capital’s investment in Biorithm acknowledges the company’s potential to transform the field of women’s healthcare with its innovative technology. Biorithm’s commitment to creating actionable value in maternal health and integrating this system across all touchpoints is said to ensure safety throughout the prenatal journey.
SEEDS Capital helps catalyze smart investments into innovative emerging Singapore-startups with extensive intellectual content and global market potential. The investment arm of Enterprise Singapore focuses its investments into strategic sectors aligned with national priorities.
On the other hand, Adaptive Capital Partners, a Singapore-based venture capital firm, predominantly invests in disruptive technology startups, particularly in the HealthTech and MedTech sectors, by employing the team’s deep experience as an operator and research background.
